{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T06:26:27Z","timestamp":1775024787457,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"ROHTO Pharmaceutical Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Cytomegalovirus (CMV) corneal endotheliitis often causes severe visual impairment owing to irreversible corneal endothelial dysfunction. Given the side effects of systemic antiviral therapy, development of an approved topical antiviral agent for CMV corneal endotheliitis is desirable. This study evaluated the efficacy and safety of topical 0.15% GCV gel, ROH-101, in the treatment of CMV corneal endotheliitis in Japanese patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Study design<\/jats:title>\n            <jats:p>Open-label, multicenter, uncontrolled, phase 3 study (jRCT2051210064).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The study was conducted from August 2021 to December 2022, with a 2-week run-in period with 0.1% fluorometholone eye drops alone, a 12-week treatment period with additional ROH-101, and a 24-week post-treatment observation period after discontinuation of ROH-101. The primary endpoint was the proportion of patients achieving a CMV DNA copy number in the aqueous humor of less than 10<jats:sup>3<\/jats:sup> copies\/mL at week 12. The clinical findings and safety were assessed over the treatment and post-treatment observation periods.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Twelve eyes of 12 patients with PCR-proven CMV corneal endotheliitis were enrolled. Treatment was discontinued in 1 eye owing to an adverse event. The other 11 eyes completed 12 weeks of treatment with 63.6% achieving the primary endpoint. The clinical findings, such as corneal edema, coin-shaped lesions, and anterior chamber inflammation, improved in all 11 eyes and did not worsen in 8 eyes that completed the post-treatment observation period. Endothelial cell density was well maintained, and none of the 11 eyes showed corneal endothelial dysfunction. Mild adverse drug reactions were reported in 3 eyes (8.3%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>ROH-101 was a safe and efficacious treatment in Japanese patients diagnosed with CMV corneal endotheliitis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10384-025-01168-5","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:23:23Z","timestamp":1744176203000},"page":"296-307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of ROH-101 (0.15% ganciclovir gel) for cytomegalovirus corneal endotheliitis: an open-label, uncontrolled, phase 3 study in Japan"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6940-1334","authenticated-orcid":false,"given":"Noriko","family":"Koizumi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichiro","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chie","family":"Sotozono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Inatomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichiro","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Hori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Uchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Soma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Fukuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitsugu","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"1168_CR1","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/0002-9394(82)90466-4","volume":"93","author":"AA Khodadoust","year":"1982","unstructured":"Khodadoust AA, Attarzadeh A. Presumed autoimmune corneal endotheliopathy. Am J Ophthalmol. 1982;93:718\u201322.","journal-title":"Am J Ophthalmol"},{"key":"1168_CR2","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/0002-9394(85)90811-6","volume":"100","author":"JB Robin","year":"1985","unstructured":"Robin JB, Steigner JB, Kaufman HE. Progressive herpetic corneal endotheliitis. Am J Ophthalmol. 1985;100:336\u20137.","journal-title":"Am J Ophthalmol"},{"key":"1168_CR3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S0002-9394(14)76251-8","volume":"112","author":"Y Ohashi","year":"1991","unstructured":"Ohashi Y, Yamamoto S, Nishida K, Okamoto S, Kinoshita S, Hayashi K, et al. Demonstration of herpes simplex virus DNA in idiopathic corneal endotheliopathy. Am J Ophthalmol. 1991;112:419\u201323.","journal-title":"Am J Ophthalmol"},{"key":"1168_CR4","first-page":"71","volume":"190","author":"PC Maudgal","year":"1980","unstructured":"Maudgal PC, Missotten L, De Clercq E, Descamps J. Varicella-zoster virus in the human corneal endothelium: a case report. Bull Soc Belge Ophtalmol. 1980;190:71\u201386.","journal-title":"Bull Soc Belge Ophtalmol"},{"key":"1168_CR5","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.ajo.2005.09.021","volume":"141","author":"N Koizumi","year":"2006","unstructured":"Koizumi N, Yamasaki K, Kawasaki S, Sotozono C, Inatomi T, Mochida C, et al. Cytomegalovirus in aqueous humor from an eye with corneal endotheliitis. Am J Ophthalmol. 2006;141:564\u20135.","journal-title":"Am J Ophthalmol"},{"key":"1168_CR6","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.ophtha.2006.07.057","volume":"114","author":"SP Chee","year":"2007","unstructured":"Chee SP, Bacsal K, Jap A, Se-Thoe SY, Cheng CL, Tan BH. Corneal endotheliitis associated with evidence of cytomegalovirus infection. Ophthalmology. 2007;114:798\u2013803.","journal-title":"Ophthalmology"},{"key":"1168_CR7","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.ajo.2006.11.026","volume":"143","author":"A Shiraishi","year":"2007","unstructured":"Shiraishi A, Hara Y, Takahashi M, Oka N, Yamaguchi M, Suzuki T, et al. Demonstration of \u201cowl\u2019s eye\u201d morphology by confocal microscopy in a patient with presumed cytomegalovirus corneal endotheliitis. Am J Ophthalmol. 2007;143:715\u20137.","journal-title":"Am J Ophthalmol"},{"key":"1168_CR8","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/ICO.0b013e31802d82fa","volume":"26","author":"T Suzuki","year":"2007","unstructured":"Suzuki T, Hara Y, Uno T, Ohashi Y. DNA of cytomegalovirus detected by PCR in aqueous of patient with corneal endotheliitis after penetrating keratoplasty. Cornea. 2007;26:370\u20132.","journal-title":"Cornea"},{"key":"1168_CR9","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ophtha.2007.04.053","volume":"115","author":"N Koizumi","year":"2008","unstructured":"Koizumi N, Suzuki T, Uno T, Chihara H, Shiraishi A, Hara Y, et al. Cytomegalovirus as an etiologic factor in corneal endotheliitis. Ophthalmology. 2008;115:292-7.e3.","journal-title":"Ophthalmology"},{"key":"1168_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/08820530802111010","volume":"23","author":"T Suzuki","year":"2008","unstructured":"Suzuki T, Ohashi Y. Corneal endotheliitis. Semin Ophthalmol. 2008;23:235\u201340.","journal-title":"Semin Ophthalmol."},{"key":"1168_CR11","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ophtha.2008.10.031","volume":"116","author":"A Anshu","year":"2009","unstructured":"Anshu A, Chee SP, Mehta JS, Tan DT. Cytomegalovirus endotheliitis in Descemet\u2019s stripping endothelial keratoplasty. Ophthalmology. 2009;116:624\u201330.","journal-title":"Ophthalmology"},{"key":"1168_CR12","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1136\/bjo.2010.182378","volume":"96","author":"HY Chu","year":"2012","unstructured":"Chu HY, Sun CC, Chuang WY, Liou SW, Ma DH, Lai CC, et al. Cytomegalovirus associated corneal endotheliitis after penetrating keratoplasty in a patient with Fuchs corneal endothelial dystrophy. Br J Ophthalmol. 2012;96:300\u20131.","journal-title":"Br J Ophthalmol"},{"key":"1168_CR13","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1136\/bjophthalmol-2017-311145","volume":"102","author":"K Kitazawa","year":"2018","unstructured":"Kitazawa K, Jongkhajornpong P, Inatomi T, Koizumi N, Kayukawa K, Wakimasu K, et al. Topical ganciclovir treatment post-Descemet\u2019s stripping automated endothelial keratoplasty for patients with bullous keratopathy induced by cytomegalovirus. Br J Ophthalmol. 2018;102:1293\u20137.","journal-title":"Br J Ophthalmol"},{"key":"1168_CR14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00417-011-1813-7","volume":"250","author":"SP Chee","year":"2012","unstructured":"Chee SP, Jap A. Treatment outcome and risk factors for visual loss in Cytomegalovirus endotheliitis. Graefes Arch Clin Exp Ophthalmol. 2012;250:383\u20139.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1168_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1136\/bjophthalmol-2013-304625","volume":"99","author":"N Koizumi","year":"2015","unstructured":"Koizumi N, Inatomi T, Suzuki T, Shiraishi A, Ohashi Y, Kandori M, et al. Clinical features and management of cytomegalovirus corneal endotheliitis: analysis of 106 cases from the Japan corneal endotheliitis study. Br J Ophthalmol. 2015;99:54\u20138.","journal-title":"Br J Ophthalmol"},{"key":"1168_CR16","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.survophthal.2021.12.006","volume":"67","author":"NR La Distia","year":"2022","unstructured":"La Distia NR, Putera I, Mayasari YD, Hikmahwati W, Pertiwi AM, Ridwan AS, et al. Clinical characteristics and treatment outcomes of cytomegalovirus anterior uveitis and endotheliitis: a systematic review and meta-analysis. Surv Ophthalmol. 2022;67:1014\u201330.","journal-title":"Surv Ophthalmol"},{"key":"1168_CR17","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.clinthera.2018.07.006","volume":"40","author":"CL Poole","year":"2018","unstructured":"Poole CL, James SH. Antiviral therapies for herpesviruses: current agents and new directions. Clin Ther. 2018;40:1282\u201398.","journal-title":"Clin Ther"},{"key":"1168_CR18","first-page":"441","volume":"1","author":"J Colin","year":"2007","unstructured":"Colin J. Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular herpes. Clin Ophthalmol. 2007;1:441\u201353.","journal-title":"Clin Ophthalmol"},{"key":"1168_CR19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1136\/bjophthalmol-2015-308238","volume":"101","author":"N Koizumi","year":"2017","unstructured":"Koizumi N, Miyazaki D, Inoue T, Ohtani F, Kandori-Inoue M, Inatomi T, et al. The effect of topical application of 0.15% ganciclovir gel on cytomegalovirus corneal endotheliitis. Br J Ophthalmol. 2017;101:114\u20139.","journal-title":"Br J Ophthalmol"},{"key":"1168_CR20","doi-asserted-by":"publisher","first-page":"e0191850","DOI":"10.1371\/journal.pone.0191850","volume":"13","author":"S Waduthantri","year":"2018","unstructured":"Waduthantri S, Zhou L, Chee SP. Intra-cameral level of ganciclovir gel, 0.15% following topical application for cytomegalovirus anterior segment infection: a pilot study. PLoS ONE. 2018;13:e0191850.","journal-title":"PLoS ONE"},{"key":"1168_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40662-020-00226-y","volume":"8","author":"AHY Wong","year":"2021","unstructured":"Wong AHY, Kua WN, Young AL, Wan KH. Management of cytomegalovirus corneal endotheliitis. Eye Vis (Lond). 2021;8:3.","journal-title":"Eye Vis (Lond)."},{"key":"1168_CR22","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/bjophthalmol-2014-306486","volume":"99","author":"M Hosogai","year":"2015","unstructured":"Hosogai M, Shima N, Nakatani Y, Inoue T, Iso T, Yokoo H, et al. Analysis of human cytomegalovirus replication in primary cultured human corneal endothelial cells. Br J Ophthalmol. 2015;99:1583\u201390.","journal-title":"Br J Ophthalmol"},{"key":"1168_CR23","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1007\/s00417-018-4111-9","volume":"256","author":"D Miyazaki","year":"2018","unstructured":"Miyazaki D, Shimizu D, Shimizu Y, Inoue Y, Inoue T, Higaki S, et al. Diagnostic efficacy of real-time PCR for ocular cytomegalovirus infections. Graefes Arch Clin Exp Ophthalmol. 2018;256:2413\u201320.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1168_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.exer.2017.06.017","volume":"161","author":"D Miyazaki","year":"2017","unstructured":"Miyazaki D, Uotani R, Inoue M, Haruki T, Shimizu Y, Yakura K, et al. Corneal endothelial cells activate innate and acquired arm of anti-viral responses after cytomegalovirus infection. Exp Eye Res. 2017;161:143\u201352.","journal-title":"Exp Eye Res"},{"key":"1168_CR25","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s10384-018-0618-1","volume":"62","author":"D Shimizu","year":"2018","unstructured":"Shimizu D, Miyazaki D, Shimizu Y, Hosogai M, Kosugi I, Inoue Y. Infection of endotheliotropic human cytomegalovirus of trabecular meshwork cells. Jpn J Ophthalmol. 2018;62:667\u201376.","journal-title":"Jpn J Ophthalmol"},{"key":"1168_CR26","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s10384-013-0268-2","volume":"57","author":"M Kandori","year":"2013","unstructured":"Kandori M, Miyazaki D, Yakura K, Komatsu N, Touge C, Ishikura R, et al. Relationship between the number of cytomegalovirus in anterior chamber and severity of anterior segment inflammation. Jpn J Ophthalmol. 2013;57:497\u2013502.","journal-title":"Jpn J Ophthalmol"},{"key":"1168_CR27","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1136\/bjo.2008.156422","volume":"94","author":"M Miyanaga","year":"2010","unstructured":"Miyanaga M, Sugita S, Shimizu N, Morio T, Miyata K, Maruyama K, et al. A significant association of viral loads with corneal endothelial cell damage in cytomegalovirus anterior uveitis. Br J Ophthalmol. 2010;94:336\u201340.","journal-title":"Br J Ophthalmol"},{"key":"1168_CR28","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.ajo.2007.12.015","volume":"145","author":"SP Chee","year":"2008","unstructured":"Chee SP, Bacsal K, Jap A, Se-Thoe SY, Cheng CL, Tan BH. Clinical features of cytomegalovirus anterior uveitis in immunocompetent patients. Am J Ophthalmol. 2008;145:834\u201340.","journal-title":"Am J Ophthalmol"},{"key":"1168_CR29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1080\/09273948.2017.1411952","volume":"26","author":"LJM Relvas","year":"2018","unstructured":"Relvas LJM, Antoun J, de Groot-Mijnes JDF, Motulsky E, Ten Dam-Van Loon NH, Makhoul D, et al. Diagnosis of cytomegalovirus anterior uveitis in two European referral centers. Ocul Immunol Inflamm. 2018;26:116\u201321.","journal-title":"Ocul Immunol Inflamm"},{"key":"1168_CR30","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1097\/ICO.0000000000000791","volume":"35","author":"NW Fan","year":"2016","unstructured":"Fan NW, Chung YC, Liu YC, Liu CJ, Kuo YS, Lin PY. Long-term topical ganciclovir and corticosteroids preserve corneal endothelial function in cytomegalovirus corneal endotheliitis. Cornea. 2016;35:596\u2013601.","journal-title":"Cornea"},{"key":"1168_CR31","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1080\/09273948.2018.1486436","volume":"27","author":"JH Hwang","year":"2019","unstructured":"Hwang JH, Ha M, Park Y, Chung SH. The effect of topical ganciclovir and corticosteroid on cytomegalovirus corneal endotheliitis in Korean patients. Ocul Immunol Inflamm. 2019;27:338\u201344.","journal-title":"Ocul Immunol Inflamm"},{"key":"1168_CR32","unstructured":"Drug Approval Package: Zirgan (ganciclovir ophthalmic gel) 0.15%. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022211_zirgan_toc.cfm Accessed 12 Jan 2024."},{"key":"1168_CR33","unstructured":"European Medicines Agency. Ganciclovir: list of nationally authorised medicinal products. https:\/\/www.ema.europa.eu\/en\/medicines\/psusa\/psusa-00001516-201606 Accessed 24 Jan 2024."},{"key":"1168_CR34","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2165\/00003495-199039040-00008","volume":"39","author":"D Faulds","year":"1990","unstructured":"Faulds D, Heel RC. Ganciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs. 1990;39:597\u2013638.","journal-title":"Drugs"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01168-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-025-01168-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01168-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T11:04:41Z","timestamp":1744801481000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-025-01168-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1168"],"URL":"https:\/\/doi.org\/10.1007\/s10384-025-01168-5","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"28 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N. Koizumi, Consultant fee, Collaborative Research Grant (M\u2019s Science Corporation), Collaborative Research Grant (ActualEyes), Consulting fee (ROHTO, Kowa), Payment for lectures (Santen, Senju, ROHTO, Kowa, Japan Tissue Engineering), owns stock in ActualEyes; D. Miyazaki,\u00a0None; S. Sugita, None; C. Sotozono, Research grant (Santen, Sun Contact Lens, Aurion Biotech), Payment or honoraria for lectures (Otsuka, Senju, Santen, Kowa, Nitto medic); T. Inatomi, Research grant (Otsuka, Santen), Payment or honoraria for presentation (Senju); H. Goto, None; A. Shiraishi, None; S. Eguchi, honoraria for lectures\u00a0(Santen, AMO, Abbvie, HOYA, Alcon, Chugai, BVI Medical); S. Ito, None; Y. Hori, None; E. Uchio, None; T. Soma, None; T. Fukuchi, Research grant (Atsuzawa Proteze, Shiga Medical Instruments, Otsuka, Retina Kitanihon, AMO, Santen, Senju, Alcon, HOYA), honoraria for lectures (Otsuka, Senju, KOWA, Nitto Medic, Santen, Novartis, Chugai); K. Hayashi, None; Y. Takeuchi, Employee (Rohto); Y. Inoue, Consulting fees (M's Science Corporation).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}